GraceFinance · Source-backed public company research
Metagenomi Therapeutics, Inc. (MGX)
Nasdaq · Manufacturing · Biological Products, (No Diagnostic Substances)
Core research established · 4/4 core data layers currently established
What Metagenomi Therapeutics, Inc. does
Overview We are an in vivo genome editing company capitalizing on our proprietary technologies to create curative genetic medicines for patients. We were founded on the science of metagenomics, the study of genetic materials recovered from the natural environment, to discover and develop a suite of novel gene editing tools potentially capable of correcting any type of genetic mutation found anywhere in the human genome. We leverage machine learning and artificial intelligence to enhance our signature gene editing systems.
Open the company story
The live GraceFinance page shows source-backed financial changes, management context, guidance, confirmed events, risks, and connected history only when the applicable evidence and relationships have been established. Missing research stays visible instead of being inferred.